This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) | MicrobiomeTrials
← Back to trials NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-05-11Est. Completion: 2030-03-31
Enrollment target: 390 participantsLocations Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara, California, United States Medical Oncology Hematology Consultants, Newark, Delaware, United States Illinois Cancer Specialists, Niles, Illinois, United States Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States Compass Oncology - West, Tigard, Oregon, United States SCRI Oncology Partners, Nashville, Tennessee, United States Texas Oncology, Austin, Texas, United States Texas Oncology - Northeast Texas, Tyler, Texas, United States Virginia Oncology Associates, Norfolk, Virginia, United States Other microbiome trials you might be interested in EGFR Overexpression Locally Advanced Solid Tumor Metastatic Solid Tumor
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…
Seoul, South Korea Est. completion Jun 2027
Bladder Urothelial Carcinoma
This study is being done to test the feasibility and accuracy of using an ultrasound-guided core needle biopsy technique…
Rochester, United States Est. completion Jul 30, 2030
Phase 2
Recruiting
Muscle-Invasive Bladder Cancer (MIBC) Urinary Bladder Cancer
For patients with HER2-expressing muscle-invasive bladder cancer (MIBC), current neoadjuvant therapies dominated by plat…
Multiple Locations Est. completion Jun 5, 2028